Media Centre


MSD abides by Medicines Australia’s Code of Conduct and the Therapeutic Goods Act.​

​Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing public press statements about our prescription medicines. We are able to issue public statements to advise registration of a new medicine, a reimbursement notice of a new medicine or any general corporate news not related to our medicines. For any specific issues please contact the Communications Manager.

Latest news:

29/08/17: Lung cancer patients die sooner in Australia than Taiwan – new analysis

Australians with advanced lung cancer are unlikely to survive longer than two years after they commence treatment, according to new research which has highlighted the limitations of chemotherapy as a front-line defence against the nation’s leading cancer killer more

10/05/2017: Federal Budget: MSD welcomes investment fund for new medicines

MSD today welcomed the Treasurer’s announcement that a new fund will be created to invest in innovative new medicines more

30/01/2017: Report shows more work is needed in fight against cardiovascular disease

MSD today welcomed many of the recommendations proposed in a report made public by the Department of Health as part of a Post-market Review into MSD’s cholesterol lowering medicine Ezetimibe (the product). more

25/01/2017: ‘Head in the sand’ attitude may put hearts at risk – new research

New research reveals that ageing Australians consider themselves thinner, fitter and healthier than they actually are, placing many in the firing line for life-threatening heart attack and stroke.more

18/01/2017: MSD welcomes new Minister for Health

MSD today welcomed the Prime Minister’s announcement that the Hon. Greg Hunt will be taking over as the Minister for Health, and Minister for Sport. more


Tanya Holloway

Communications Manager

Phone: +61 407 695 885​​